[1]方美华,陈丽珠,冯建捷.子宫颈癌、子宫癌和卵巢癌患者血浆D-二聚体检测的临床意义[J].现代检验医学杂志,2017,32(05):145-147,151.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　FANG Mei-hua,CHEN Li-zhu,FENG Jian-jie.Clinical Significance of Plasma D-Dimer Detection in Cervical Cancer,Uterine Cancer and Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2017,32(05):145-147,151.[doi:10.3969/j.issn.1671-7414.2017.05.017]
点击复制

子宫颈癌、子宫癌和卵巢癌患者血浆D-二聚体检测的临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
145-147,151
栏目:
检验与临床
出版日期:
2017-11-02

文章信息/Info

Title:
Clinical Significance of Plasma D-Dimer Detection in Cervical Cancer,Uterine Cancer and Ovarian Cancer
文章编号:
1671-7414(2017)05-145-04
作者:
方美华1; 陈丽珠1; 冯建捷2
1.漳州市云霄县中医院,福建云霄 363300; 2.漳州招商局经济技术开发区第一医院,福建漳州 363000
Author(s):
FANG Mei-hua1; CHEN Li-zhu1; FENG Jian-jie2
1.Yunxiao Traditional Chinese Medicine Hospital in Zhangzhou City,Fujian Yunxiao 363300,China; 2.the FirstHospital of Zhangzhou China Merchants Economic and Technological Development Zone,Fujian Zhangzhou 363000,China
关键词:
子宫颈癌;  子宫癌;  卵巢癌;  D-二聚体;  临床分期;  诊断
分类号:
R737.3; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.05.017
文献标志码:
A
摘要:
目的 探讨子宫颈癌、子宫癌和卵巢癌患者血浆D-二聚体水平检测的临床意义。方法 收集2013年10月～2015年7月在云霄县中医院和漳州开发区第一医院就诊的子宫颈癌患者35例,子宫癌患者32例,卵巢癌患者30例,测定血浆D-二聚体水平,分别与子宫颈炎、子宫肌瘤、卵巢囊肿患者和健康对照比较,并分析D-二聚体水平与国际妇产科联盟(FIGO)分期的关系,采用受试者工作特征(ROC)曲线分析D-二聚体对3种恶性肿瘤的诊断价值。结果 子宫颈癌组D-二聚体水平高于子宫颈炎组,子宫癌组高于子宫肌瘤组,卵巢癌组高于卵巢囊肿组,差异均具有统计学意义(t=5.91～7.17,均P<0.01)。子宫颈癌、子宫癌与卵巢癌之间差异无统计学意义(F=0.10,P>0.05)。子宫颈炎组、子宫肌瘤组和卵巢囊肿组之间差异无统计学意义(F=2.47,P>0.05),事后检验,子宫颈炎组高于子宫肌瘤组,差异具有统计学意义(P<0.05)。与健康对照组比较,子宫颈癌组、子宫癌组、卵巢癌组、子宫颈炎组和卵巢囊肿组明显增高,差异具有统计学意义(t=2.43～7.53,P<0.01～0.05),子宫肌瘤组与健康对照组差异无统计学意义(t=1.04,P>0.05)。子宫颈癌、子宫癌和卵巢癌不同FIGO分期患者,血浆D-二聚体水平不同(F=15.06～19.02,P均<0.01),与分期的升级呈正相关(r=0.625～0.855,P均<0.01)。D-二聚体诊断三种肿瘤的ROC曲线下面积(AUC)分别为0.964,0.980和0.983,灵敏度为82.9%,90.6%和86.7%,特异度均为100%,具有较高诊断价值。结论 子宫颈癌、子宫癌和卵巢癌均存在血栓形成和纤溶亢进,血浆D-二聚体水平可以作为诊断的参考指标。
Abstract:
Abstract:Objective To explore the clinical significanceof detection of plasma D-dimer in patients with cervical cancer, uterine cancer and ovarian cancer.Methods Total 35 cervical cancer patients,32 uterine cancer patients and 30 ovarian cancer patients were collected from Yunxiao Traditional Chinese Medicine Hospital of Zhangzhou city and the First Hospital of Zhangzhou China Merchants Economic and Technological Development Zone from October 2013 to July 2015.The plasma D-dimer was detected and compared with cervicitis,hysteromyoma,ovarian cyst and healthy control respectively.Relativity between the level of plasma D-dimer with the International Federation of Gynecology and Obstetrics(FIGO)staging was anslyzed.The diagnostic value of plasma D-dimer in cervical cancer,uterine cancer and ovarian cancer was assessed by receiver operating characteristic(ROC)curves.Results The level of plasma D-dimer in the cervical cancer group was significantly higher than that in the cervicitis group,the uterine cancer group was higher than that in the uterine leiomyoma group,and the ovarian cancer group was higher than that in the ovarian cyst group too(t=5.91～7.17,all P<0.01).It was no significantly differentia compare with cervical cancer group,uterine cancer group and ovarian cancer group(F=0.10,P>0.05).Plasma D-dimer level in cervicitis group,hysteromyoma group and ovarian cyst group was no significantly differentia(F=2.47,P>0.05)but it was significantly high in cervicitis than hysteromyoma at post test(P<0.05).Compared with healthy control group,the plasma D-dimer level was significantly rise in cervical cancer,uterine cancer,uterine cancer,cervicitis and ovarian cyst(t=2.43～7.53,P<0.01～0.05),while no significantly differentia in hysteromyoma(t=1.04,P>0.05).It was significantly differentia and increases as the FIGO staging in cervical cancer,uterine cancer and uterine cancer(F=15.06～19.02,all P<0.01,r=0.625～0.855,all P<0.01).The area under the ROC curve(AUC)of the three tumors diagnosed by D-dimer was 0.964,0.980 and 0.983,with sensitivity of 82.9%,90.6% and 86.7% respectively,and specificity of all 100%,which was of high diagnostic value.Conclusion There are hyperactivity of thrombosis and fibrinolysis in cervical cancer,uterine cancer and ovarian cancer.The plasma D-dimer levels can be used as the reference index of diagnosis and staging.

参考文献/References:

[1] Obel JC,Friberg G,Fleming GF.Chemotherapy in endometrial cancer[J].Clin Advanc Hematol Oncol,2006,4(6):459-468.
[2] 黄学梅,喻 垚,王亚丽,等.D-二聚体在恶性肿瘤中的研究进展[J].国际检验医学杂志,2012,33(15):1850-1853. Huang XM,Yu Y,Wang YL,et al.The research progress of D-Dimer inmalignant tumor[J].Int J Lab Med,2012,33(15):1850-1853.
[3] Pecorelli S.Revised FIGO staging for carcinoma of the vulva,cervix,andendometrium[J].International Journal of Gynecology and Obstetrics,2009,105(2):103- 104.
[4] Donati MB,Lorenzet R.Thrombosis and cancer:40 years of research[J].Thromb Res,2012,129(3):348-352.
[5] 门剑龙,钟殿胜,任 静.血栓标志物评估恶性肿瘤患者静脉血栓风险[J].中华肿瘤杂志,2015,37(4):283-289. Men JL,Zhong DS,Ren J.Estimation of venous th-rom boembolism risk with thrombotic biomarkers in cancer patients[J].Chin J Oncol,2015,37(4):283-289.
[6] 宋文炜.血浆D-二聚体检测对甲状腺癌患者的临床意义[J].现代检验医学杂志,2016,31(6):138-140. Song WW.Clinical significance of plasma D-dimer testing in patients with thyroid cancer[J].J Mod Lab Med,2016,31(6):138-140.
[7] 申 旺,凌寿坚,叶丽燕,等.血浆D-二聚体检测在非小细胞肺癌中的临床意义[J].检验医学,2015,30(4):318-320. Shen W,Ling SJ,Ye LY,et al.Clinical significance of plasma D-dimer detection in patients with non-small cell lung cancer[J].Laboratory Medicine,2015,30(4):318-320.
[8] 张红雨,马兴璇.联合检测D-二聚体和CA153在乳腺癌诊治中的临床意义[J].现代检验医学杂志,2015,30(2):137-138. Zhang HY,Ma XX.The clinical significance of combined detection ofD- Dimer and CA153 in the diagnosis and treatment of breast cancer[J].J Mod Lab Med,2015,30(2):137-138.
[9] 葛建新,封 革,王 平.消化系统恶性肿瘤患者血浆D-二聚体的临床意义[J].现代中西医结合杂志,2012,21(33):3717-3719. Ge JX,Feng G,Wang P.The clinical significance of plasma D-Dimerin patients with digestive system malignant tumor[J].Modern Journal of Integrated Traditional Chinese and Western Medicine,2012,21(33):3717-3719.
[10] Vahid Dastjerdi M,Ahmari S,Alipour S,et al.The comparison ofplasma D-dimer levels in benign and malignant tumors of cervix,ovary and uterus[J].Int J Hematol Oncol Stem Cell Res,2015,9(3):107-111.
[11] 高云潮.国内肿瘤标志物诊断性试验论文存在的问题[J].放射免疫学杂志,2006,19(6):512-514. Gao YC.Problems in the diagnostic test papers of tumor markers in China[J].J of Radioimmunology,2006,19(6):512-514.
[12] 顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(4):141-143. Gu YF,Zhu ZL,Zhang JY,et al.Selecting the best cut-off point of serumHE-4 in ovarian cancer by BOC curve[J].J Mod Lab Med,2015,30(4):141-143.

备注/Memo

备注/Memo:
作者简介:方美华(1970),女,本科,副主任检验师,主要研究方向:肿瘤的实验室诊断,E-mail:532272692@qq.com。 通讯作者:冯建捷(1971-),女,副主任检验师,主要研究方向:出血与血栓疾病的实验室诊断。
更新日期/Last Update: 1900-01-01